283 related articles for article (PubMed ID: 26979038)
1. [NEW ANTIFUNGAL DRUGS FOR PREVENTION AND TREATMENT OF VISCERAL MYCOSES].
Pilmis B; Lortholary O; Lanternier FL
Rev Prat; 2015 Dec; 65(10):1334-9. PubMed ID: 26979038
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole: a role for the newest broad-spectrum triazole.
Slavin MA; Thursky KA
Lancet; 2016 Feb; 387(10020):726-8. PubMed ID: 26684608
[No Abstract] [Full Text] [Related]
3. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
4. Isavuconazonium sulfate for the treatment of fungal infection.
Walker RC; Zeuli JD; Temesgen Z
Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
[TBL] [Abstract][Full Text] [Related]
5. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
[TBL] [Abstract][Full Text] [Related]
6. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
[TBL] [Abstract][Full Text] [Related]
7. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
8. [The future of antifungal agents].
Maesaki S
Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
[No Abstract] [Full Text] [Related]
9. [Outcome analysis of caspofungin in combination with voriconazole for treatment of 12 hematologic malignancies cases with invasive fungal infection].
Sun HL; Zhou X; Shen YF
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):558-9. PubMed ID: 22338183
[No Abstract] [Full Text] [Related]
10. Clinical indications for newer antifungal agents.
Naeger-Murphy N; Pile JC
J Hosp Med; 2009 Feb; 4(2):102-11. PubMed ID: 19219926
[TBL] [Abstract][Full Text] [Related]
11. [Infectious diseases: progress in diagnosis and treatment. Topics: IV. Towards containing infectious diseases: 3. Development of new antifungal drugs].
Yoshida M
Nihon Naika Gakkai Zasshi; 2012 Nov; 101(11):3185-91. PubMed ID: 23342592
[No Abstract] [Full Text] [Related]
12. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Ananda-Rajah MR; Kontoyiannis D
Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
[TBL] [Abstract][Full Text] [Related]
13. New pharmacological opportunities for the treatment of invasive mould diseases.
Ledoux MP; Toussaint E; Denis J; Herbrecht R
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
Guinea J; Bouza E
Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
[TBL] [Abstract][Full Text] [Related]
15. [Antifungal therapy update: new drugs and medical uses].
FortĂșn J
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():38-44. PubMed ID: 22305668
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
Wang JF; Xue Y; Zhu XB; Fan H
Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
[TBL] [Abstract][Full Text] [Related]
17. [New development in the treatment of deep-seated mycoses].
Maesaki S
Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1993-8. PubMed ID: 17929445
[No Abstract] [Full Text] [Related]
18. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
20. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]